Table 1. Immunostimulatory mAbs currently in clinical development.
| Target(s) | mAb | Aliases | Isotype | Source | Activity | Owner |
|---|---|---|---|---|---|---|
| CD27 | CDX-1127 | 1F5 | n.a. | Human | Agonist | Celldex |
| CD40 | Chi Lob 7/4 | - | IgG1 | Chimeric | Agonist | Cancer Research UK |
| CP-870,893 | - | IgG2 | Human | Agonist | Pfizer | |
| Dacetuzumab | SGN-40 huS2C6 |
IgG1 | Humanized | Agonist | Seattle Genetics | |
| Lucatumumab | HCD122 | IgG1 | Human | Agonist | Novartis Pharmaceuticals | |
| CD274 (PD-L1, B7-H1) |
BMS-936559 | MDX-1105 | IgG4 | Human | Antagonist | Bristol–Myers Squibb |
| MEDI4736 | - | IgG1 | Human | Antagonist | Medimmune | |
| MPDL3280A | RG7446 | IgG1 | Human | Antagonist | Genentech (Roche) | |
| MSB0010718C | - | n.a. | Human | Antagonist | Serono (Merck) | |
| CTLA4 | Ipilimumab | BMS-734016 MDX-010 MDX-101 Yervoy® |
IgG1κ | Human | Antagonist | Bristol–Myers Squibb |
| Tremelimumab | CP-675,206 Ticilimumab |
IgG2 | Human | Antagonist | Pfizer | |
| KIR | IPH2101 | 1–7F9 | IgG4 | Human | Antagonist | Innate Pharma |
| Lirilumab | BMS-986015 IPH2102 |
IgG4 | Human | Antagonist | Bristol–Myers Squibb | |
| PDCD1 (PD-1) |
AMP-224 | - | IgG1 chimera | Human | Antagonist | Amplimmune (Medimmune, AstraZeneca) |
| Lambrolizumab | MK-3475 | IgG4 | Humanized | Antagonist | Merck | |
| Nivolumab | BMS-936558 MDX1106 ONO-4538 | IgG4 | Human | Antagonist | Bristol–Myers Squibb | |
| Pidilizumab | CT-011 | IgG1κ | Humanized | Antagonist | CureTech | |
| MHCII | IMP321 | - | IgG1 chimera | Human | Agonist | Immutep |
| PDCD1LG2 (PD-L2, B7-DC) |
rHIgM12B7 | - | IgM | Human | Agonist | Mayo Foundation |
| TGFβ1 | Fresolimumab | GC1008 | IgG4κ | Human | Antagonist | Sanofi–Aventis |
| TNFRSF4 (OX40) |
9B12 | - | IgG1 | Murine | Agonist | AgonOx |
| MEDI6469 | - | n.a. | Murine | Agonist | Medimmune (AstraZeneca) |
|
| TNFRSF9 (CD137, 4–1BB) |
Urelumab | BMS-663513 | IgG4 | Human | Agonist | Bristol-Myers Squibb |
| PF-05082566 | - | IgG2 | Human | Agonist | Pfizer | |
| TNFRSF18 (GITR) |
TRX518 | - | IgG1 | Humanized | Agonist | Tolerex |
Abbreviations: CTLA4, cytotoxic T lymphocyte-associated protein 4; KIR, killer cell immunoglobulin-like receptor; mAb, monoclonal antibody; MHCII, MHC Class II; n.a., not available; PDCD1, programmed cell death 1; PDCD1LG2, PDCD1 ligand 2; TGFβ1, transforming growth factor β1; TNFRSF, tumor necrosis factor receptor superfamily.